Abstract: The incidence of adenocarcinoma of esophagogastric junction (AEG) is increasing, but its treatment strategy is still controversial. Surgery is the main strategy of multidisciplinary treatment. Siewert classification and TNM staging play a decisive role in the choice of operative approach, clinical decision and prognosis. Perioperative chemoradiotherapy plays an important role in the multidisciplinary treatment of AEG, and more researches support neoadjuvant therapy in patients with AEG. What′s more, targeted therapy has become an integral part of multidisciplinary treatment of AEG with the constantly emergence of targeted drugs. In addition, the particularity of AEG determines that its treatment requires multidisciplinary cooperation, and the multidisciplinary team is expected to improve the prognosis of AEG patients.